Category Archives: Co-infections
Approach to acute kidney injury in HIV-infected patients in South Africa
Background: HIV-infected patients have an increased risk of renal disease. Current first-line antiretroviral therapy contains tenofovir disoproxil fumarate (TDF), which has nephrotoxic potential, characterised by proximal tubular cell injury. This...
Incidence and prevalence of bacteriologically confirmed pulmonary tuberculosis among adolescents and young adults: A systematic review
The burden of tuberculosis (TB) among adolescents and young adults in endemic settings is poorly characterised. This study aimed to review published and unpublished estimates of the incidence and prevalence...
Incidence and risk factors for prediabetes and diabetes mellitus among HIV-infected adults on antiretroviral therapy: A systematic review and meta-analysis
OBJECTIVE: To summarize evidence on the rates and drivers of progression from normoglycemia to prediabetes and/or diabetes mellitus (hereafter “diabetes”) in antiretroviral treatment (ART)-exposed HIV-infected people. METHODS: We searched EMBASE,...
The effect of human immunodeficiency virus and cytomegalovirus infection on infant responses to vaccines: A review
The success of prevention of mother to child transmission programs over the last two decades has led to an increasing number of infants who are exposed to human immunodeficiency virus...
Active case finding for communicable diseases in prison settings: Increasing testing coverage and uptake among the prison population in the European Union/European Economic Area
Prison populations are disproportionally affected by communicable diseases when compared with the general community because of a complex mix of socioeconomic determinants and environmental factors. Tailored and adequate health care...
Sustained virological response in special populations with chronic hepatitis C using interferon-free treatments: A systematic review and meta-analysis of observational cohort studies
BACKGROUND AND OBJECTIVES: Hepatitis C treatment has changed considerably in recent years, and many interferon (IFN)-free therapies are now available. Considering the high rates of sustained virological response (SVR) presented...
Linking private, for-profit providers to public sector services for HIV and tuberculosis co-infected patients: A systematic review
BACKGROUND: Tuberculosis (TB) is the leading cause of infectious disease deaths worldwide and is the leading cause of death among people with HIV. The World Health Organization (WHO) has called...
Strategies for improving the lives of US women aged 40 and above living with HIV/AIDS: An evidence map
BACKGROUND: While in its early years the HIV epidemic affected primarily the male and the young, nowadays, the population living with HIV/AIDS is approximately 24% women, and its age composition...
Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high HIV and tuberculosis burden countries: A systematic review
AIMS: Efavirenz (EFV) and Rifampicin-Isoniazid (RH) are cornerstone drugs in HIV-tuberculosis (TB) co-infection treatment but with complex drug interactions, efficacy and safety challenges. We reviewed recent data on EFV and...
Comorbidities and treatment outcomes in multidrug resistant tuberculosis: A systematic review and meta-analysis
Little is known about the impact of comorbidities on multidrug resistant (MDR) and extensively drug resistant (XDR) tuberculosis (TB) treatment outcomes. We aimed to examine the effect of human immunodeficiency...
Tuberculosis treatment outcomes in Ethiopia from 2003 to 2016, and impact of HIV co-infection and prior drug exposure: A systematic review and meta-analysis
BACKGROUND: Knowledge of tuberculosis (TB) treatment outcomes is substantially needed to assess the performance of national TB controls programs (NTPs). To date, the overall estimates of treatment outcomes have not...
CD4 cell count threshold for cryptococcal antigen screening of HIV-infected individuals: A systematic review and meta-analysis
Background: Current guidelines recommend screening all people living with human immunodeficiency virus (PLHIV) who have a CD4 count ≤100 cells/µL for cryptococcal antigen (CrAg) to identify those patients who could benefit...
